|By Marketwired .||
|June 16, 2014 08:00 AM EDT|
LONDON, ONTARIO -- (Marketwired) -- 06/16/14 -- Tribute Pharmaceuticals Canada Inc. ("Tribute" or "the Company") (TSX VENTURE:TRX) (OTCQB:TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced today that its President and Chief Executive Officer, Rob Harris, will present an update on the Company and its corporate activities, at the Bloom Burton & Co. ("Bloom Burton") Annual Healthcare Investor Conference, to be held on Wednesday, June 18 at the Toronto Board of Trade.
Bloom Burton's third annual healthcare investor conference features Canada's premier publicly-traded and venture-backed private companies. The event will attract Canadian, U.S. an European investors who are interested in the latest developments in Canadian healthcare companies.
Tribute's corporate presentation will be available on the Company's website at http://www.tributepharma.com following the presentation.
About Tribute Pharmaceuticals Canada Inc.
Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.
Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution 2%) and Collatamp G® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to develop and commercialize Bezalip® SR in the U.S. and has the exclusive right to sell bilastine a product licensed from Faes Farma for the treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria (hives) in Canada. The exclusive license is inclusive of prescription and non- prescription rights for bilastine, as well as adult and pediatric presentations in Canada. This product is subject to receiving Canadian regulatory approval.
Tribute Pharmaceuticals' Forward Looking Statement
This press release contains certain forward-looking statements about Tribute as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward- looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to
future events or results. Forward-looking statements, by their nature, are subject to risks and uncertainties, Tribute actual results could differ materially from those anticipated in these forward- looking statements as a result of numerous factors, any of which could cause actual results to vary materially from current results or anticipated future results. See Tribute reports filed with the Canadian Securities Regulatory Authorities and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties that could cause actual results to differ materially from results referred to in forward-looking statements. Tribute assumes no obligation to update the information contained in this press release to update forward-looking statements to reflect changed assumptions, the occurrence of anticipated events or changes in future operating results, financial condition or business over time.
Bezalip®SR and Soriatane® are registered trademarks and under license from Actavis Group PTC ehf. Cambia® is a registered trademark and under license from Depomed, Inc. Collatamp G® is a registered trademark and under license EUSA Pharma (Europe) Limited.
For further information on Tribute visit the Company's website: http://www.tributepharma.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Oct. 24, 2016 11:00 PM EDT Reads: 1,993
Oct. 24, 2016 10:00 PM EDT Reads: 904
Oct. 24, 2016 09:45 PM EDT Reads: 1,360
Oct. 24, 2016 08:45 PM EDT Reads: 1,026
Oct. 24, 2016 08:30 PM EDT Reads: 1,325
Oct. 24, 2016 08:15 PM EDT Reads: 2,593
Oct. 24, 2016 07:30 PM EDT Reads: 3,204
Oct. 24, 2016 07:15 PM EDT Reads: 1,049
Oct. 24, 2016 07:15 PM EDT Reads: 1,166
Oct. 24, 2016 06:15 PM EDT Reads: 4,757
Oct. 24, 2016 05:45 PM EDT Reads: 1,501
Oct. 24, 2016 05:00 PM EDT Reads: 3,636
Oct. 24, 2016 05:00 PM EDT Reads: 3,902
Oct. 24, 2016 04:45 PM EDT Reads: 1,570
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, will contrast how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He will show the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He will also have live demos of building immutable pipe...
Oct. 24, 2016 04:30 PM EDT Reads: 1,591